NASDAQ:OBIO Orchestra BioMed Q2 2025 Earnings Report $2.66 -0.06 (-2.21%) Closing price 08/13/2025 04:00 PM EasternExtended Trading$2.70 +0.04 (+1.50%) As of 04:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Orchestra BioMed EPS ResultsActual EPS-$0.50Consensus EPS -$0.51Beat/MissBeat by +$0.01One Year Ago EPSN/AOrchestra BioMed Revenue ResultsActual Revenue$0.84 millionExpected Revenue$0.78 millionBeat/MissBeat by +$57.00 thousandYoY Revenue GrowthN/AOrchestra BioMed Announcement DetailsQuarterQ2 2025Date8/12/2025TimeBefore Market OpensConference Call DateMonday, August 18, 2025Conference Call Time3:00PM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Orchestra BioMed Earnings HeadlinesOrchestra BioMed reports Q2 EPS (50c), consensus (51c)August 12 at 4:01 PM | msn.comOrchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business UpdatesAugust 12 at 10:58 AM | finanznachrichten.deIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, and has now reached every AI company in America... including Nvidia, Microsoft, and Meta. | Altimetry (Ad)Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business UpdatesAugust 12 at 8:14 AM | globenewswire.comBrokerages Set Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Target Price at $14.00August 9, 2025 | americanbankingnews.comOrchestra BioMed rises as trial for antihypertensive drug expandsAugust 8, 2025 | msn.comSee More Orchestra BioMed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Orchestra BioMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orchestra BioMed and other key companies, straight to your email. Email Address About Orchestra BioMedOrchestra BioMed (NASDAQ:OBIO) operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.View Orchestra BioMed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why BigBear.ai Stock's Dip on Earnings Can Be an Opportunity CrowdStrike Faces Valuation Test Before Key Earnings ReportPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals?Why SoundHound AI's Earnings Show the Stock Can Move HigherAirbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings BeatIs Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Upcoming Earnings Palo Alto Networks (8/18/2025)Medtronic (8/19/2025)Home Depot (8/19/2025)Analog Devices (8/20/2025)Synopsys (8/20/2025)TJX Companies (8/20/2025)Lowe's Companies (8/20/2025)Workday (8/21/2025)Intuit (8/21/2025)Walmart (8/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access